EUVIMEDOpdag EUVIMED
Open access

Design, Synthesis, and In Vitro Evaluation of a PSMA‐Targeted Doxorubicin Conjugate

Sahil Kumar iD, Mrityunjay Tyagi, Riddhi Pal, Birija S Patro, Dibakar Goswami iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70406 ↗

At a glance

Journal article in ChemMedChem, 2026. Written by Sahil Kumar and 4 co-authors. Institution: Bio-Organic Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India. Major MEDLINE topics: Doxorubicin, Glutamate Carboxypeptidase II, Drug Design, Antigens, Surface. 51 references. The full text is freely available in PubMed Central. Funded by: Department of Atomic Energy, Government of India.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Clinical treatment of prostate cancer, particularly metastatic castration‐resistant prostate cancer (mCRPC), mainly depends on targeting prostate‐specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII). Toward this, small molecule–drug conjugates (SMDCs), consisting of a PSMA‐targeting ligand along with a chemotherapeutic, have emerged as an important targeted therapeutic tool. Herein, we have designed 39 ligands with varied targeting heads and linkers and have analyzed their efficacy in silico using molecular docking and molecular dynamics simulation. The best‐docked compound was further synthesized, conjugated with doxorubicin via an acid‐labile imine linkage to yield a novel PSMA–Dox conjugate. This conjugate was evaluated in vitro in PSMA‐positive (LNCaP and C4‐2 cells) and PSMA‐negative (PC3 cells) to establish its selectivity toward PSMA, as well as to ascertain its selective cytotoxicity toward PSMA‐positive cells. Further, cell cycle analysis confirmed the efficacy of the conjugate to induce apoptosis in PSMA‐positive cancer cells. Thus, this study demonstrates a new SMDC which can serve as a template for creating new analogs with enhanced targeting and anticancer efficacy.

Subjects

MeSH terms (MEDLINE)

DoxorubicinGlutamate Carboxypeptidase IIDrug DesignAntigens, SurfaceAntineoplastic AgentsHumansApoptosisDrug Screening Assays, AntitumorMolecular Docking SimulationStructure-Activity RelationshipCell Line, TumorCell ProliferationMaleMolecular StructureDose-Response Relationship, DrugMolecular Dynamics Simulation

Author keywords

PSMAdoxorubicinpeptideprostate cancertargeted chemotherapy

Substances

DoxorubicinGlutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, humanAntineoplastic Agents

Authors and institutions

  • Bio-Organic Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India.
  • Homi Bhabha National Institute, Anushaktinagar, Mumbai, India.

ORCID profiles: Sahil Kumar, Dibakar Goswami

Funding

  • Department of Atomic Energy, Government of India

Cite

APA

Kumar, S., Tyagi, M., Pal, R., Patro, B. S., & Goswami, D. (2026). Design, Synthesis, and In Vitro Evaluation of a PSMA‐Targeted Doxorubicin Conjugate. ChemMedChem. https://doi.org/10.1002/cmdc.70406

Vancouver

Kumar S, Tyagi M, Pal R, Patro BS, Goswami D. Design, Synthesis, and In Vitro Evaluation of a PSMA‐Targeted Doxorubicin Conjugate. ChemMedChem. 2026. doi:10.1002/cmdc.70406

BibTeX
@article{Kumar2026,
  author = {Kumar, Sahil and Tyagi, Mrityunjay and Pal, Riddhi and Patro, Birija S and Goswami, Dibakar},
  title = {Design, Synthesis, and In Vitro Evaluation of a PSMA‐Targeted Doxorubicin Conjugate},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70406}
}
Start for free →